Obstetrics and Gynecology · 2003 · 66 citations · 48 references
MedicineMaternal HealthObstetricsCost-effectiveness AnalysisHiv PreventionReproductive HealthAntenatal AssessmentHiv TestingMaternal Disease PreventionMother-to-child Transmission PreventionPregnancyPrenatal CareCost-effectivenessHiv Antibody DetectionHiv Screening In PregnancyHuman Immunodeficiency Virus ScreeningHuman Immunodeficiency Virus TestingMaternal Health EconomicsPregnancy Hiv TestingPrenatal Hiv Testing
OBJECTIVE: To estimate the incremental societal costs and effectiveness of a second human immunodeficiency virus (HIV) antibody test during the third trimester of pregnancy compared with no second test. METHODS: We used a decision tree in this cost-effectiveness analysis to model outcomes among pregnant women in high-risk communities and nationwide who received an initial, negative HIV antibody test during the first trimester. The main outcome measure was discounted costs per year of infant life saved. RESULTS: In high-risk communities with estimated HIV incidence of 6.2 per 1000 person-years, a second HIV test compared with no second test would detect 192 infections in women, prevent approximately 37 infant infections, and save 655 infant life-years per 100,000 women tested. Net savings would be 5.2 million US dollars. Applied to an estimated national incidence of.17 per 1000 person-years, a second test would detect 5.3 infections in women, prevent 1.3 infant infections, and save 23.3 infant life-years per 100,000 women tested. Net costs would be 1.06 million US dollars, or 45,708 US dollars for each year of infant life saved. A second test would result in net savings in populations with HIV incidence of 1.2 per 1000 person-years or higher. CONCLUSION: Health care providers serving women in communities with an HIV incidence of 1 per 1000 person-years or higher should strongly consider implementing a second voluntary universal HIV test during the third trimester. Providers serving lower-risk communities should pilot second testing to assess community-specific costs.
48
Ronald A. Arky · 1994 · 2.6K citations
Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness
Tammy O. Tengs, Miriam E. Adams, Joseph S. Pliskin et al. · Risk Analysis · 1995 · 1.3K citations
Pharmacy, Pharmacoeconomics, Cost-effectiveness Analysis +11
Effect of Breastfeeding and Formula Feeding on Transmission of HIV-1
Ruth Nduati, Grace C. John, Dorothy Mbori‐Ngacha et al. · JAMA · 2000 · 927 citations